Oncology and Immuno-Oncology INSIGHTS

New PBMC-humanized Mice Support Efficient NK-cell Engraftment

photo from New PBMC-humanized Mice Support Efficient NK-cell Engraftment

Favored for their relative speed, versatility, and translational relevance, humanized mice engrafted with human peripheral blood mononuclear cells (PBMCs) are the go-to preclinical models for evaluating T-cell-dependent immunotherapies. However, lacking important human cytokine signals, huPBMC-NOG and other PBMC models fail to support engraftment of important human immune cell subtypes, such as natural killer (NK) cells. This limits their utility for many studies. Recent work from Taconic Biosciences...  Read More

Webinar Q&A — Next Generation Humanized Mice in IO

photo from Webinar Q&A — Next Generation Humanized Mice in IO

The preclinical research community responded enthusiastically to Dr. Paul Volden's recent webinar, Next Generation Humanized Mice in Immuno-Oncology, the second webinar in a two-part series on humanized mice for preclinical immuno-oncology (IO). Several questions had to be cut from the presentation for time and are presented here, in full. Preclinical Immuno-Oncology Q&A Dr. Paul Volden (PV): The number of cells obtained from individual hematopoietic stem cell (HSC)...  Read More

Webinar Q&A — Humanized Mice in Preclinical Immuno-Oncology

photo from Webinar Q&A — Humanized Mice in Preclinical Immuno-Oncology

Dr. Paul Volden recently presented a webinar on humanized mice in preclinical immuno-oncology research. Many of the questions you submitted to his Q&A session went unanswered due to time constraints, so here's the full Q&A. General Immuno-Oncology Questions Dr. Paul Volden (PV): I would not recommend commercially available humanized models for most cancer vaccine studies. To get sufficient vaccine response, you need interaction between antigen presenting cells...  Read More

Humanized Mice in Safety and Toxicity Testing

photo from Humanized Mice in Safety and Toxicity Testing

Humanized mice are invaluable tools for studying the function of the human immune system in an in vivo context, with applications for studying infectious disease, immuno-oncology, and immunology. Recently, Ryoji Ito and colleagues at the Central Institute for Experimental Animals in Japan demonstrated their efficacy in assessing the safety of chemotherapeutic drug candidates1. Humanized Mice and Myelotoxicity Testing Myelotoxicity is a common treatment-related adverse effect for antineoplastic...  Read More

Video: Mouse Models Used to Study Immuno-oncology

photo from Video: Mouse Models Used to Study Immuno-oncology

Taconic Biosciences' Dr. Philip Dubé discusses mouse models used to study immuno-oncology in this video excerpt from the webinar, "Advanced Toolkit For Syngeneic Tumor Modeling in Mice". There are essentially two types of models used in pre-clinical immuno-oncology research: Syngeneic models — a mouse tumor is implanted into a genetically identical and immuno-competent host Humanized models — severely immuno-deficient mice are implanted with both a human immune...  Read More

Seminar: Humanized Mice in Preclinical Bone Metastasis Studies

photo from Seminar: Humanized Mice in Preclinical Bone Metastasis Studies

All are welcome to Biocom's continuing education seminar on the use of humanized mice in immuno-oncology and bone metastasis studies on April 12, 2018 at Larkspur Landing. Immuno-Oncology Seminar BioCom will hold an in-person continuing education seminar to explore new study design options in immuno-oncology supported by novel humanized mouse models, including a case study on how one particular humanized mouse could be used to study cancer...  Read More

Immunogenic peptide from PSF1 identified as potential new cancer vaccine target

photo from Immunogenic peptide from PSF1 identified as potential new cancer vaccine target

Although much of the press for immuno-oncology (IO) has focused on checkpoint inhibitors, researchers are exploring many other types of IO therapeutics. Other types of IO therapies under development include bi-specific antibodies, CAR-T cells, and cancer vaccines. Researchers at Shionogi and Osaka University recently published a paper1 describing identification of a new tumor antigen with the potential for targeting via a cancer vaccine. Previous research showed that...  Read More

Webinar Review: Immuno-oncology and the Microbiome

photo from Webinar Review: Immuno-oncology and the Microbiome

In a recent webinar, Dr. Benjamin Cuiffo of Biomodels addressed the role of microbiome in preclinical immuno-oncology research. There is growing evidence that microbial imbalance (dysbiosis) is associated with many illnesses, including inflammation, autoimmune disease, and even cancer — but many researchers fail to account for its impact in preclinical study design. If you missed it, here's a summary of the key developments discussed during Dr. Cuiffo's...  Read More

Breakthrough Model for Immunotherapy Research

photo from Breakthrough Model for Immunotherapy Research

Rodent models engrafted with human immune cells are important tools for preclinical evaluation of immunotherapies. However, humanized immune system (HIS) models have largely failed to support the long-term engraftment and survival of human natural killer (NK) cells, an immune cell population that is essential to an increasing number of cancer therapies being developed. This was a significant barrier to progress in preclinical immuno-oncology research. In their latest...  Read More

Care of Immunodeficient Mice and Rats

photo from Care of Immunodeficient Mice and Rats

Immunodeficient rodents require special husbandry and housing in order to remain healthy and provide optimum experimental performance. Below are recommendations for care and housing of immunodeficient rodents. Upon Delivery of Immunodeficient Rodents Most facilities receive multiple animal deliveries on the same day. These shipments carry rodents of varying strains and health status. Rather than unpacking deliveries randomly, Taconic Biosciences recommends sorting transit cages based on immune status...  Read More

Close

Welcome! Tell us a little about yourself